Other Novo Nordisk and OpenAI forge alliance to drive speedy drug development Pharmaceutical TechnologyNovo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.OtherRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaceutical Technology Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025. OtherRead full story Post navigation Previous: Revolution rockets on strong pancreatic cancer dataNext: Travere claims first FDA OK in rare kidney disease FSGS Related Stories Other ‘Seismic shift’ as obesity overtakes cancer for R&D returns pharminent May 5, 2026 Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026 Other FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech pharminent April 29, 2026
